WO2008141511A8 - A HUMAN ANTI-TNFα MONOCLONAL ANTIBODY AND THE USE THEREOF - Google Patents
A HUMAN ANTI-TNFα MONOCLONAL ANTIBODY AND THE USE THEREOF Download PDFInfo
- Publication number
- WO2008141511A8 WO2008141511A8 PCT/CN2007/070044 CN2007070044W WO2008141511A8 WO 2008141511 A8 WO2008141511 A8 WO 2008141511A8 CN 2007070044 W CN2007070044 W CN 2007070044W WO 2008141511 A8 WO2008141511 A8 WO 2008141511A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tnfα
- antibody
- human anti
- human
- monoclonal antibody
- Prior art date
Links
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract 3
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 102000057041 human TNF Human genes 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
A protein specifically binding to human TNFα (tumor necrosis factor α) is disclosed, i.e. human anti-TNFα monoclonal antibody derived from human B cells. The light and heavy chain of the antibody have the amino acid sequence as shown in SEQ ID NO: 3 and SEQ ID NO: 4, respectively. Also disclosed are the encoded sequences of the human anti- TNFα antibody, its Fab antibody and the peglated Fab antibody. The present invention further provides the uses of the antibodies in the preparation of the medicament for treatment of TNFα-related inflammation.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2007/070044 WO2008141511A1 (en) | 2007-05-22 | 2007-05-22 | A HUMAN ANTI-TNFα MONOCLONAL ANTIBODY AND THE USE THEREOF |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2007/070044 WO2008141511A1 (en) | 2007-05-22 | 2007-05-22 | A HUMAN ANTI-TNFα MONOCLONAL ANTIBODY AND THE USE THEREOF |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008141511A1 WO2008141511A1 (en) | 2008-11-27 |
WO2008141511A8 true WO2008141511A8 (en) | 2009-07-09 |
Family
ID=40031397
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2007/070044 WO2008141511A1 (en) | 2007-05-22 | 2007-05-22 | A HUMAN ANTI-TNFα MONOCLONAL ANTIBODY AND THE USE THEREOF |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2008141511A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101896502B (en) | 2009-03-20 | 2012-10-17 | 刘庆法 | Anti-human TNFα monoclonal antibody, molecular evolution and its application |
CN102167741B (en) * | 2010-02-25 | 2014-05-14 | 上海百迈博制药有限公司 | A fully human anti-TNF-α monoclonal antibody, its preparation method and use |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040136989A1 (en) * | 2002-07-19 | 2004-07-15 | Abbott Laboratories S.A. | Treatment of vasculitides using TNFalpha inhibitors |
EP1578799B8 (en) * | 2002-12-02 | 2011-03-23 | Amgen Fremont Inc. | Antibodies directed to tumor necrosis factor and uses thereof |
CN100393748C (en) * | 2003-11-06 | 2008-06-11 | 上海中信国健药业有限公司 | Human tumour necrosin antibody, its preparation and medicinal composition |
KR100772800B1 (en) * | 2003-11-17 | 2007-11-01 | 주식회사유한양행 | Variable regions of monoclonal antibodies that recognize human tumor necrosis factor α and genes encoding them |
CN101111521B (en) * | 2004-12-29 | 2011-08-24 | 株式会社柳韩洋行 | Tumor necrosis factor-α specific humanized antibody |
-
2007
- 2007-05-22 WO PCT/CN2007/070044 patent/WO2008141511A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2008141511A1 (en) | 2008-11-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12020551978A1 (en) | Anti-interleukin-17a antibody, pharmaceutical composition thereof and use thereof | |
NZ603499A (en) | Human cytomegalovirus neutralizing antibodies and uses thereof | |
NZ700473A (en) | Human antigen binding proteins that bind beta-klotho, fgf receptors and complexes thereof | |
NZ602780A (en) | Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
NZ602892A (en) | Antibodies that bind human cd27 and uses thereof | |
WO2008017828A3 (en) | Antibodies specific for human cd98 heavy antigen | |
NZ597466A (en) | Recombinant anti-epidermal growth factor receptor antibody compositions | |
EP1578799B8 (en) | Antibodies directed to tumor necrosis factor and uses thereof | |
TW200635945A (en) | Antibodies against IL-13 receptor alpha 1 and uses thereof | |
NZ600768A (en) | Human antibodies to human angiopoietin-like protein 4 | |
WO2006087637A3 (en) | Anti her2/neu antibody | |
GEP20094829B (en) | Fully human antibodies against human 4-1bb (cd137) | |
TW200745164A (en) | Gene recombination antibodies composition | |
NZ595224A (en) | Specific binding proteins and uses thereof | |
JP2014518615A5 (en) | ||
GEP20146050B (en) | Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors | |
NZ587198A (en) | Monoclonal antibodies against the rgm a protein and uses thereof | |
RS52484B (en) | Antibodies to cd40 | |
EA201190132A1 (en) | HUMANIZED ANTIBODIES, CONNECTING CD19, AND THEIR APPLICATION | |
NZ703653A (en) | Anti-fap antibodies and methods of use | |
EP2163562A3 (en) | IL-1beta binding antibodies and fragments thereof | |
NZ599193A (en) | Siglec 15 antibodies in treating bone loss-related disease | |
NZ595792A (en) | Antibodies specific to cadherin-17 | |
NZ594682A (en) | Fully human antibodies specific to cadm1 | |
EA032189B9 (en) | Isolated human monoclonal antibodies against tissue factor pathway inhibitor (tfpi) and pharmaceutical composition comprising same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07721667 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07721667 Country of ref document: EP Kind code of ref document: A1 |